Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 18/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16369642 | 1.00 | FFAR2 (1.00) | FFAR2LMNAMEN1KMT2ATSHR | |
| SCHEMBL22945149 | 0.88 | FFAR2 (0.79) | FFAR2LMNAMEN1KMT2ATSHR | |
| SCHEMBL16369613 | 0.77 | FFAR2 (1.00) | FFAR2LMNAMEN1KMT2A | |
| SCHEMBL16369612 | 0.77 | FFAR2 (1.00) | FFAR2LMNAMEN1KMT2A | |
| SCHEMBL1564845 | 0.76 | LMNA (0.69) | FFAR2LMNAMEN1KMT2A | |
| SCHEMBL11309036 | 0.75 | FFAR2 (0.80) | FFAR2LMNAMEN1KMT2A | |
| SCHEMBL27891187 | 0.75 | FFAR2 (0.62) | FFAR2LMNAMEN1KMT2ATSHR | |
| SCHEMBL20788538 | 0.75 | FFAR2 (1.00) | FFAR2LMNAMEN1KMT2A | |
| SCHEMBL2021216 | 0.75 | FFAR2 (0.80) | FFAR2LMNAMEN1KMT2A | |
| SCHEMBL1107000 | 0.75 | ADORA2A (0.68) | FFAR2LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130989-A9 | ALLERGY TREATMENT | PROTA THERAPEUTICS PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| CN-121818627-A | Application of 4-CMTB in preparation of medicines for treating sepsis | 重庆市急救医疗中心 | 2026-04-10 | — | — | CN | disclosed |
| CN-121818627-A | Application of 4-CMTB in preparation of medicines for treating sepsis | 重庆市急救医疗中心 | 2026-04-10 | — | — | CN | disclosed |
| US-20250381267-A1 | ALLERGY TREATMENT | PROTA THERAPEUTICS PTY LTD (AU) | 2025-12-18 | — | — | US | disclosed |
| WO-2024216281-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CIRCADIAN RHYTHM DISORDERS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-117679444-A | Bacteroides thetaiotaomicron and application of MCM enzyme thereof in maintaining intestinal barrier steady state and improving intestinal inflammation | 上海交通大学医学院附属瑞金医院 | 2024-03-12 | — | — | CN | disclosed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230049005-A1 | ALLERGY TREATMENT | PROTA THERAPEUTICS PTY LTD (AU) | 2023-02-16 | — | — | US | disclosed |
| CN-115584328-A | Bifidobacterium pseudolongum and application thereof | 中国科学院上海巴斯德研究所 | 2023-01-10 | — | — | CN | disclosed |
| WO-2021127736-A1 | ALLERGY TREATMENT | PROTA THERAPEUTICS PTY LTD (AU) | 2021-07-01 | — | — | WO | disclosed |
| US-20190134179-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10130695-B2 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | VEDANTA BIOSCIENCES, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180000921-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9764019-B2 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | VEDANTA BIOSCIENCES, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160144014-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES (US) | 2016-05-26 | — | — | US | disclosed |
| EP-3019181-A2 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | Puretech Ventures, LLC (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006355-A2 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | PURETECH VENTURES, LLC (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130989-A9 | ALLERGY TREATMENT | FCER2, HRH2, FCGR3B | FFAR2 854/4885LMNA 4456/4885MEN1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.